30 September 2015
MSD Animal Health Launches INNOVAX®-ILT Vaccine in European Union Immunises Poultry against Highly Contagious Respiratory Virus
MSD Animal Health today announced the launch of INNOVAX®-ILT, the company’s novel vaccine that, in a single shot, immunises poultry against infectious laryngotracheitis (ILT) as well as Marek’s disease for use in the European Union. INNOVAX-ILT is MSD Animal Health’s first vector vaccine to launch in the EU, and is the first and only vector vaccine available in the EU to immunise against infectious laryngotracheitis. The vaccine will be available to customers in the UK from November 2015.
“Infectious laryngotracheitis is a significant concern across the poultry industry since the virus – as well as some existing preventative measures – can have a negative impact on growth and overall performance of the chickens,” said Dr. Rik Koopman, Global Technical Director, MSD Animal Health. “What makes INNOVAX -ILT a true advance is that with a single shot; it helps farmers effectively immunise their poultry against ILT virus as well as Marek’s disease, without compromising growth or causing respiratory reactions that impair performance. MSD Animal Health is proud to offer a vaccine that will improve poultry health and efficiency.”
Infectious laryngotracheitis is an acute, highly contagious, herpesvirus infection of chickens and other poultry characterized by severe dyspnea (gasping or shortness of breath), coughing and rales (rattling or abnormal lung sounds). Typically, affected birds also become anorectic (reduced appetite), or inactive. ILT also causes a drop in egg production in laying birds. Infectious laryngotracheitis has been a growing and costly problem in recent years for poultry producers, and the infection can affect broilers as well as breeders and layers.
INNOVAX -ILT utilises the herpesvirus of turkey (HVT) as a vector or carrier virus for infectious laryngotracheitis antigens; HVT has a good safety profile for chickens and also immunises against Marek’s disease, another herpesvirus that causes tumors, immunosuppression and sometimes mortality. The vaccine allows birds to develop immunity against infectious laryngotracheitis and Marek’s disease before they are exposed to the viruses that cause these diseases. The vaccine also helps producers reduce labour costs because it requires only a single dose at the hatchery; the vaccine is administered via subcutaneous injection in day-old chicks. The vaccine offers long protection against ILT (at least 60 weeks) in long-lived chickens such as broiler breeders and commercial layers.
Innovax-ILT is only available upon prescription from your veterinary surgeon. For additional information, contact your veterinary surgeon or a member of the MSD Animal Health poultry team on 01908 685685.
About MSD Animal Health
Today's MSD is a global healthcare leader working to help the world be well. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, NJ, USA., is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com or connect with us on LinkedIn.
MSD forward-Looking Statement
This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of MSD’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; MSD’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of MSD’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
MSD undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).